- Tenax Therapeutics Inc TENX has received a statement of approval from the United States Patent and Trademark Office (USPTO). Patent Application with Claim Coverage the use of IV levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
- The patent is expected to last until 2040. It will provide the company with significant additional intellectual property (IP) protection for the use of levosimendan in the treatment of PH-HFpEF patients in the US
- The approval notice further builds on Tenax’s intellectual property for levosimendan, which includes U.S. Patent No. 11,213,524 issued January 2022, covering all medical uses of the subcutaneous formulation of levosimendan in humans.
- The protection that this patent will provide is based on key discoveries from the HELP study.
- The results of the HELP study showed that levosimendan-treated PH-HFpEF patients benefited from a statistically significant improvement in a 6-minute walk distance of 29 meters compared to placebo.
- Price promotion: TENX shares are up 92.3% to $3.25 on the latest check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
